Volume 20, Issue 1 (4-2018)                   yafte 2018, 20(1): 85-98 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Fallah rajabpour zare M, Rakhshan K, Aboutaleb N, Nikbakht F, Bakhshesh M, Azizi Y. Apigenin improves myocardial function and attenuates cardiotoxicity induced by doxorubicin in male rats. yafte 2018; 20 (1) :85-98
URL: http://yafte.lums.ac.ir/article-1-2519-en.html
,Physiology research center and Department of physiology, faculty of medicine, Iran University of Medical Sciences, Tehran, Iran
Abstract:   (24198 Views)
Background: Doxorubicin has been used in the treatment of malignancies, including lymphoma, leukemia and breast cancer. Cardiotoxicity is the main adverse effect of doxorubicin. Apigenin, as a flavonoid, has antioxidant, anti-inflammatory and anti tumoral properties. The aim of this study is the assessment of the effect of apigenin on cardiotoxicity induced by doxorubicin.
Materials and Methods: 60 male wistar rats were divided into 6 groups. Cardiotoxicity was induced by 6 injections of doxorubicin (2 mg/kg, ip) over 12 days. The treatment groups received orally 25, 50 and 75 mg/kg/day apigenin for 12 days simultaneously with cardiotoxicity induction.
Results: The heart weight to body weight ratio showed no significant difference between different groups. In the apigenin group (25 mg/kg), EF and FS showed  a significant increase (P<0.05) and LVEDs, LDH and CK-MB showed a significant decrease, in comparison to the cardiotoxicity group.
Conclusion: Apigenin prevents LDH and CK-MB elevation and also EF and FS reduction and improves cardiac tissue changes and leads to a decrease in cardiac damage induced by doxorubicin. 
Full-Text [PDF 595 kb]   (2230 Downloads)    
Type of Study: Research | Subject: فیزیولوژی انسانی
Received: 2017/08/19 | Accepted: 2018/04/18 | Published: 2018/04/18

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Yafteh

Designed & Developed by : Yektaweb